Tanzeum Available for Type 2 Diabetes

Share this content:
Tanzeum Available for Type 2 Diabetes
Tanzeum Available for Type 2 Diabetes

GlaxoSmithKline announced that Tanzeum (albiglutide) subcutaneous injection is now available for the treatment of type 2 diabetes in adults as adjunct to diet and exercise.

Tanzeum, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a once weekly treatment indicated for use in combination with other antidiabetic medications. It has been approved with a Risk Evauation and Mitigation Strategy (REMS) to ensure that the benefits outweigh the potential risk of medullary thyroid carcinoma and the risk of acute pancreatitis.

Tanzeum for subcutaneous injection is available as a 30-mg or 50-mg single-dose pen in 4-count cartons.

For more information call (888) 825-5249 or visit Tanzeum.com.

You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus